Further assessment of these B cells’ antigen-presenting capacity, including their expressions of MHC class II molecules and co-stimulatory signals, would be critical for understanding their contribution to anti-tumor immunity and their potential to enhance cross-priming of CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.